The program times are listed in Central European Time (CEST)
ORAL GLP-1RA: NOVEL BUT NOT NEW - Industry Symposium Supported by Novo Nordisk
Session description - Discuss how semaglutide can be delivered as an oral formulation and drive early GLP-1RA initiation while also benefiting individuals with longstanding type 2 diabetes. Large peptide molecules generally require injection for medication delivery. This session will introduce you to the technology that facilitates semaglutide to be delivered as a simple, daily oral tablet. Explore frequently asked questions from people with diabetes and learn where an oral GLP-1RA fits into their daily routine.